CHIMERIC THERAPEUTICS

CAPITAL RAISING PRESENTATION
FEBRUARY 2022

DISCLAIMER

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Chimeric Therapeutics Limited ACN 638 835 828 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

5. Certain statements contained in this presentation, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

6. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

INVESTMENT HIGHLIGHTS

- **Rapid Growth**
  Fastest growing cell therapy pipeline in Australia with 7 novel assets in development

- **Innovative & Diversified Portfolio**
  Diversified portfolio leveraging both T Cell and NK cell innovation and individualized and off the shelf platforms

- **Extensive Clinical Development**
  4 planned clinical programs in 2022 and 8 planned clinical programs by 2023 in 10+ types of blood cancers and solid tumours

CHIMERIC THERAPEUTICS

- **Early Positive Clinical Signals**
  Initial positive ph. 1 clinical data in GBM with dose cohort 4 complete 2H22

- **Expedited Regulatory Pathway**
  Anticipated fast to market development with FDA registration from positive Phase 2 data

- **World Renowned Partners**
  Research collaborations with University of Pennsylvania and City of Hope- world renowned cell therapy centres

- **Proven Cell Therapy Experience**
  Industry leading management team with 40+ years of critical cell therapy expertise (incl 4 of 5 FDA approvals)

- **Capital Raising & Balance Sheet**
  Accelerated non-renounceable entitlement offer to raise up to approximately $18.1m at $0.17 per share with free attaching 1:1 listed option exercisable at $0.255 and expiring on 31 March 2024. A$31.5m pro-forma cash balance post raise. Key programs funded into 2023 and past Phase 1A GBM readout. Potential A$27.2m of additional funding from option exercise option.

CHIMERIC MANAGEMENT TEAM

GLOBAL EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION

EXPERIENCE

40+ Years of Cell Therapy Experience

EXPERTISE

25+ Development Programs

PROVEN

4/5 Of the FDA Approved CAR T Cell Therapies

WORLD RENOWNED ADVISORS AND COLLABORATORS

CELLULAR IMMUNOTHERAPY SCIENTIFIC ADVISORY BOARD



RESEARCH COLLABORATORS

Penn
University of Pennsylvania

City of Hope

Case Western Reserve University Est. 1826

RESEARCH PARTNERS

OncoBay Clinical

CHIMERIC THERAPEUTICS: FINANCIAL SNAPSHOT

Market Information (as of February 17, 2022)

Market Cap As of February 17, 2022	$69M
H/L	0.44c/0.20c
Shares on Issue	330M
Board / Management Ownership	~30%
Pro-forma Cash balance	$31.5M

Assumes capital raising is fully subscribed

ASX: CHM

52 Week Overview



Listed: January 18, 2021

CHIMERIC THERAPEUTICS:
AT IPO VS NOW

IPO January 2021

Share Price Following Listing $0.44
Market Cap ~$145m

Assets: 1

Disease Areas: 1

Clinical Trials: 1
(in progress/ planned)

July 2021

Share Price $0.36
Market Cap ~$119m

Assets: 2

Disease Areas: 5

Clinical Trials: 1+ 2
(in progress + planned)

February 2022

Share Price $0.20
Market Cap ~$69M

Assets: 7

Disease Areas: 10+

Clinical Trials: 2+ 6
(in progress + planned)

ADVANCED CELL THERAPY PORTFOLIO AND PIPELINE

Fast to market development with registration from Phase 2 trial



1. Phase 3 may not be required if Phase 2 is registrational

7
Unique Assets

8
Clinical Programs by 2023

10+
Disease Areas

2021 KEY MILESTONES

Significant achievements and growth in our first year on the ASX

CREATE AN INDUSTRY LEADING PORTFOLIO

- ✓ CDH17 Licensed from University of Pennsylvania
- ✓ CORE NK Platform option from Case Western Reserve University
- ✓ Exclusive Licensing Option in SRA with University of Pennsylvania

ACCELERATE CLINICAL DEVELOPMENT

- ✓ CLTX CAR T GBM Ph. 1 Dose Level 1 Complete
- ✓ CLTX CAR T GBM Ph. 1 Dose Level 2 Complete
- ✓ CLTX CAR T GBM Ph. 1 Initial positive data
- ✓ CLTX CAR T in Melanoma Preclinical Data
- ✓ CORE NK Ph. 1A Study Completion

ENSURE TECHNICAL OPERATIONS READINESS

- ✓ CLTX CAR T vector production
- ✓ CDH17 CAR T plasmid production
- ✓ CDH17 CAR T vector pilot run
- ✓ CDH17 and CLTX CAR T drug product manufacturing partner identified
- ✓ Supply chain partner identified

ENHANCE CELL THERAPY EXPERTISE

- ✓ Sponsored Research Agreement with UPenn
- ✓ Onco Bay CRO Collaboration
- ✓ Eliot Bourk, Chief Business Officer and Li Ren, VP Technical Operations
- ✓ Cellular Immunotherapy Scientific Advisory Board

CHM 1101 (CLTX CAR T)

Encouraging Initial Phase 1 Data with 2nd cohort complete

Dose level 1 (44 X 10^6) CLTX CAR T cells singular route of intratumoral administration	**Dose level 2** (88 X 10^6) CLTX CAR T cells dual routes of intratumoral and intraventricular administration
No dose limiting toxicities, generally well tolerated with no cytokine release syndrome	
Persistence of CHM 1101 (CLTX CAR T) cells shown throughout treatment	Under assessment
Local disease stability in 75% (3/4) of patients	Local disease stability in 67% (2/3) of patients
Local progression shown at week 8	Under assessment

"This preliminary data is encouraging as it demonstrates safety with dual routes of administration.

We now look forward to advancing the trial to higher dose levels which may provide more therapeutic benefit to patients"

Behnam Badie, M.D., Professor and Chief, Division of Neurosurgery; Director, Brain Tumor Program, Department of Surgery, City of Hope.

2022 KEY VALUE CREATION CATALYSTS

EXTENSIVE OPPORTUNITIES FOR VALUE CREATION IN 2022

Collaborations and Partnership		
CLTX CAR T	**CDH17 CAR T**	**CORE NK**
• GBM Ph1 Dose Level 3 Completion • GBM Ph1 Dose Level 4 Completion • Melanoma IND Acceptance	• Completion of Preclinical Work • Vector Manufacturing • Solid Tumour IND Acceptance	• Executed License and SRA • CORE NK Ph. 1 Data • Technical Operations Partner • Next Generation CORE NK Platform Initiation • CLTX CAR NK Initiation
In Licensing Novel Cell Therapies		

POTENTIAL VALUE REALIZATION PATHWAYS

Cell and gene therapy is the most active investment sector in biotech today

In the past 18-24 months, 16 of the largest pharmaceutical companies have added cell and gene therapy products to their portfolio

ACQUISITION

Gilead acquisition of Kite	$11.9B
Celgene acquisition of Juno	$9B
Astellas acquisition of Xyphos	$665M
Kite acquisition of Cell Design Labs	$567M

PARTNERSHIP

Janssen & Fate	$3B
Kite & Shoreline	$2.3B
Vertex & CRISPR	$900M
Eli Lilly & Precision	$525M
Merck & Artiva	$1.8B
Roche & Adaptimmune	$3B

INDEPENDENT DEVELOPMENT

7 NOVEL ASSETS

10+ DISEASE AREAS

The cell and gene therapy market was valued at $5B USD in 2021 and is expected to reach $37B USD by 2027

Source: Refer Appendix

USE OF FUNDS & FUNDING CAPACITY

Pro-Forma funding of A$58.7m post capital raising and assuming option exercise
Company key CLTX and CDH17 programs funded into 2023 and past Phase 1 GBM readout

PRO-FORMA FUNDING	A$M
Existing Cash Balance[1]	$13.4
Capital Raising[2]	$18.1
Attaching Options Exercise[3]	$27.2
TOTAL	$58.7

CAPITAL RAISE		A$M
CHM 1101 (CLTX CAR T)		
	Licensing & SRA Fees	$4.3
	Phase 1 GBM Clinical Trial Expansion	$5.1
	Phase 1 Solid Tumour Basket Trial	$1.0
CHM 1101 Use of Funds		$10.4
CHM 2101 (CDH17 CAR T)		
	Licensing and SRA Fees	$1.0
	Phase 1	$3.4
CHM 2101 Use of Funds		$4.4
CHM 0201 (CORE NK)		
	Licensing and SRA Fees	$2.3
CHM 0201 Use of Funds		$2.3
Offer Costs and Working Capital		$1.0
TOTAL		$18.1

[1]As of December 31, 2021
[2]Assumes capital raising is fully subscribed
[3]Assumes options are fully exercised

AN EMERGING GLOBAL CELL THERAPY COMPANY

- ✓ **Innovative & Diversified Portfolio**
  7 novel individualized (autologous) T cell and off the shelf (allogeneic) NK cell therapies
- ✓ **Broad Therapeutic Focus**
  Development 10+ types of blood cancers and solid tumours for extensive commercial opportunity
- ✓ **Extensive Clinical Development**
  4 planned clinical programs in 2022 and 8 planned clinical programs by 2023
- ✓ **Early Positive Signals**
  Initial positive phase 1 clinical data in GBM and promising preclinical data in NETs
- ✓ **World Renowned Partners**
  Research collaborations with world renowned cell therapy centres and scientists
- ✓ **Industry Leading Experience**
  Internal team of experts in successful cell therapy development and commercialization

OFFER OVERVIEW

CAPITAL RAISING OVERVIEW

Chimeric is raising up to approximately A$18.1m via an accelerated non-renounceable entitlement offer

Offer Structure	▪ A 1 for 3.15 accelerated non-renounceable entitlement offer of new shares to existing shareholders to raise up to approximately A$18.1m ▪ Entitlement offer will compromise an Institutional Entitlement Offer and a Retail Entitlement Offer. The retail entitlement offer will include a top up facility ▪ Record date to identify shareholders entitlement: Wednesday 23rd February 2022.
Offer Pricing	▪ Offer Price of A$0.17 per share, which represents: – A discount of 15.0% to the last close of A$0.20 per share on 18 February 2022 – A discount of 18.3% to the 5-day VWAP of A$0.208 per share to 18 February 2022 – A discount of 26.4% to the 30-day VWAP of $0.231 per share to 18 February 2022
Attaching Option	▪ Participants will receive one free attaching option for every one share subscribed for under the Offer ▪ The option is intended to be listed on the ASX with an exercise price of A$0.255 and expiry date of 31 March 2024 ▪ New Options shall only be issued to Institutional Shareholders if, at the issuance date, they hold at least the number of New Shares they subscribed for under the Institutional Entitlement Offer
Ranking	▪ New shares under the entitlement offer will rank pari passu with existing ordinary shares in CHM

USE OF FUNDS

CAPITAL RAISE		A$M
CHM 1101 (CLTX CAR T)		
	Licensing & SRA Fees	$4.3
	Phase 1 GBM Clinical Trial Expansion	$5.1
	Phase 1 Solid Tumour Basket Trial	$1.0
CHM 1101 Use of Funds		$10.4
CHM 2101 (CDH17 CAR T)		
	Licensing and SRA Fees	$1.0
	Phase 1	$3.4
CHM 2101 Use of Funds		$4.4
CHM 0201 (CORE NK)		
	Licensing and SRA Fees	$2.3
CHM 0201 Use of Funds		$2.3
Offer Costs and Working Capital		$1.0
TOTAL		$18.1

KEY DELIVERABLES

Program	Use of Funds	Key Deliverables
CHM 110 1 (CLTX CAR T)	$4.3M	• Completion of solid tumour preclinical data package • COH licensing payments
	$5.1M	• Expansion of GBM trial to new sites • Completion of Phase 1A GBM Dose Escalation • Expansion cohort design
	$1.0M	• Phase 1 IND submission
CHM 2101 (CDH17 CAR T)	$1.0M	• Completion of solid tumour preclinical data package
	$3.4M	• IND Submission • GMP Vector and Drug Product Manufacturing Readiness
CHM 0201 (CORE NK Platform)	$2.3M	• Execution of licensing agreement • Initiation of enhancements for CHM 0301 • Initiation of CAR NKs

OFFER TIMETABLE

Indicative capital raising timetable[1]	Date
Trading halt and announcement of accelerated non-renounceable entitlement offer	Monday, 21 February 2022
Institutional Offer Closes	Monday, 21 February 2022
Record date to identify shareholders entitlement to participate in the offer	Wednesday, 23 February 2022
Announcement of results of Institutional Offer and trading halt lifted – shares recommence trading on ASX (ex-entitlement)	Wednesday, 23 February 2022
Settlement of New Shares under Institutional Offer	Monday, 28 February 2022
Issue of New Shares under Institutional Offer	Tuesday, 29 February 2022
Retail Offer Opens	Monday, 28 February 2022
Retail Offer Closes	Friday, 11 March 2022
Issue of New Shares under Retail Offer and Issue of New Options under the Retail and Institutional Offer	Friday, 18 March 2022
Normal trading for New Shares under Retail Offer and Issue of New Options under the Retail and Institutional Offer	Monday, 21 March 2022

[1]The timetable is indicative only and subject to change by the Company and Lead Manager, subject to the Corporations Act and other applicable laws

Cell Therapy Overview

OUR MISSION

To Bring the Promise of Cell Therapy to Life

We believe that novel cellular therapies have the promise to cure cancer.

Our mission is to to bring that promise to life for more patients with cancer.



'We can now conclude that **CAR-T cells can actually cure patients**'
Carl June, MD, University of Pennsylvania

"These are patients with an abysmal prognosis, really without hope and now with CAR T therapy we're really able to give them a chance.
This is a revolution. It's a revolution in cancer care. This is the tip of the iceberg,"

Fred Locke, MD, Moffit Cancer Center

"Oncologists, cancer doctors, researchers don't use words like 'cure' lightly or easily or frankly very often, **we really believe we can start to use the word 'cure.'"**
David Porter, MD, University of Pennsylvania

What is Cell Therapy?

Cell therapy is the transfer of live cells into a patient to help lessen or cure a disease.
Cell therapy in its most basic form is a blood transfusion.
Today's cell therapies can involve the engineering of live cells to attack specific diseases



Genes programmed with the information needed to make special receptors called "Chimeric Antigen Receptors" (CARs) are inserted into live cells.



The Chimeric Antigen Receptors (CARs) become expressed on the cell surface and are activated to search for specific cancer cells.



Once the Chimeric Antigen Receptor (CAR) finds the specific cancer cell it was programmed to find, it attaches itself to the cancer cell and sends a signal to kill it.

Cell Therapy Global Investment

Reflecting the Promise of Cell Therapy

Global Cell & Gene Therapy Investment (USD)

2021 — **$23.1B**
↑ 16% from 2020

2020 — **$19.9B**
↑ 100% from 2019

2019 — **$9.8B**
raised in 2019

$18.0B
US Developers
53% increase YoY

$3.3B
European Developers
8% decrease YoY

$2.2B
APAC Developers
4% decrease YoY

https://alliancerm.org/wp-content/uploads/2022/01/Phacilitate-Presentation-FINAL.pdf

January 2022 Collaborations (USD)

Bristol-Myers Squibb
CENTURY THERAPEUTICS

$150M[1]
Upfront

moderna
carisma THERAPEUTICS

$80M[2]
Upfront

BAYER
Mammoth Biosciences

$40M[3]
Upfront

1. https://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-and-bristol-myers-squibb-enter-strategic
2. https://carismatx.com/moderna-and-carisma-establish-collaboration-to-develop-in-vivo-engineered-chimeric-antigen-receptor-monocytes-car-m-for-oncology/
3. https://www.businesswire.com/news/home/20220109005059/en/Bayer-and-Mammoth-Biosciences-to-Collaborate-on-Novel-Gene-Editing-Technology

BUILDING A CELL THERAPY PORTFOLIO

ALTERNATIVE CELL TYPES: T CELLS vs. NK CELLS

T Cells



T cells are part of the adaptive immune system- primed to recognize a specific threat on a foreign cell surface

- **Proven curative efficacy in blood cancers**
- **Primed to target and attack specific antigens**
- **Direct killing of cancer cells**

NK Cells



Natural Killer (NK) cells are part of the innate immune response – responding to anything that appears to be non-self

- **Intrinsic ability to identify and kill cancer cells**
- **Direct and indirect killing of cancer cells**
- **Low risk of safety concerns**

BUILDING A CELL THERAPY PORTFOLIO

ALTERNATIVE CELL SOURCES: INDIVIDUALIZED VS. OFF THE SHELF

Individualized Therapies
(Autologous)



- Proven curative efficacy in blood cancers
- Reduced potential for a patient's immune system to attack the cells
- Established long term cell persistence

Use a patients own cells to make their individualized therapy

Off the Shelf Therapies
(Allogeneic)



- Rapidly available, off the shelf
- Scalable manufacturing with reduced costs
- Healthier starting material

Use cells from a healthy donor to make therapies for 100's of patients

OUR STRATEGY

To bring the promise of cell therapy to life

INNOVATION

Develop innovative cell therapies with the most curative potential for patients

EXPERIENCE

Leverage a team of cell therapy pioneers and experts

ACCELERATION

Focus on rapid patient access and asset maximization

CHIMERIC CELL THERAPY PORTFOLIO

A DIVERSIFIED PIPELINE WITH CUTTING EDGE INNOVATION

Novel Design

T Cells

Autologous

(personal)

- **CLTX CAR T** (ICT/ ICV) — GBM Phase 1 ongoing
- CLTX CAR T (IV) — Solid Tumour Phase 1 planned 2022
- **CDH17 CAR T** — Solid Tumour Phase 1 planned 2022

City of Hope.

Penn

NK Cells

Allogeneic

(off-the-shelf)

- CORE-NK Platform — Phase 1 Complete
- Next Gen. CORE-NK Platform — Ph. 1 Planned 2023
- CLTX CAR-NK — Ph.1 Planned 2023
- CDH17 CAR-NK — Ph.1 Planned 2023
- Undisclosed CAR-NK — Ph.1 Planned 2023

Case Western Reserve University EST. 1826

INDIVIDUALIZED (AUTOLOGOUS) T CELL PROGRAMS

CHM 1101: (CLTX CAR T)

A FIRST AND BEST IN CLASS CAR T CELL THERAPY

First in Class CLTX CAR T

CHM 1101 is a first-in-class CAR T, utilizing Chlorotoxin, a 36-amino acid peptide derived from deathstalker scorpion venom as its tumor targeting domain.



Broad Recognition and Binding

In preclinical studies, CHM 1101 was shown to more specifically and broadly target GBM cells than other immunotherapies



Potent In Vivo Activity

In preclinical studies, CHM 1101 demonstrated potent anti-tumor activity in vivo with significantly improved survival in mice



CHM 1101 (CLTX CAR T)

Ongoing Phase 1 Clinical Trial

Primary Objective: To assess the safety of CLTX CAR T cells and to determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan

Phase 1 Clinical Trial Design: 4 dose levels and 2 routes of administration

DOSE LEVEL 1 **COMPLETE**	DOSE LEVEL 2 **COMPLETE**	DOSE LEVEL 3 **IN PROGRESS**	DOSE LEVEL 4
			
Intratumoral Administration	Intratumoral and Intraventricular Administration	Intratumoral and Intraventricular Administration	Intratumoral and Intraventricular Administration
ICT Administration Total dose: 44 X 10^6	ICT & ICV Administration Total dose: 88 X 10^6	ICT & ICV Administration Total dose: 220 X 10^6	ICT & ICV Administration Total dose: 440 X 10^6

Approximately 18 -36 patients with recurrent or progressive GBM over 24 months

CHM 1101 (CLTX CAR T)

Encouraging Initial Phase 1 Data with 2nd cohort complete

Dose level 1 (44 X 10^6) CLTX CAR T cells singular route of intratumoral administration	**Dose level 2** (88 X 10^6) CLTX CAR T cells dual routes of intratumoral and intraventricular administration
No dose limiting toxicities, generally well tolerated with no cytokine release syndrome	
Persistence of CHM 1101 (CLTX CAR T) cells shown throughout treatment	Under assessment
Local disease stability in 75% (3/4) of patients	Local disease stability in 67% (2/3) of patients
Local progression shown at week 8	Under assessment

"This preliminary data is encouraging as it demonstrates safety with dual routes of administration.

We now look forward to advancing the trial to higher dose levels which may provide more therapeutic benefit to patients"

Benham Badie, M.D., Professor and Chief, Division of Neurosurgery; Director, Brain Tumor Program, Department of Surgery, City of Hope.

CLTX CAR T

Expansion into Metastatic Melanoma

Metastatic melanoma is the most serious and life-threatening type of skin cancer

309k[1] New cases worldwide each year

62k[2] Deaths worldwide each year

~17k[3] New cases in Australia each year

~1.3k[3] Deaths in Australia each year

Early staining of a melanoma cell line confirms strong MMP-2 expression in melanoma and a consistently strong correlation between MMP-2 expression and CLTX binding



1. Global Burden of Disease Cancer Collaboration, JAMA Oncol 2019
2. SEER https://seer.cancer.gov accessed October 2021
3. https://www.canceraustralia.gov.au/cancer-types/melanoma/statistics accessed Feb 20, 2022

CDH17 CAR T

A FIRST IN CLASS CAR T CELL THERAPY

The first CDH17 CAR T cell therapy in development in the world

Broad Applicability to address unmet medical needs in gastrointestinal (GI) cancers such as colorectal and gastric cancer as well as in neuroendocrine tumours

Over a Decade of Development at the world-renowned cell therapy centre, the University of Pennsylvania

- home to the 1st FDA approved CAR T therapy
- 1st amongst global universities for cell therapy patents

3 year sponsored research agreement with University of Pennsylvania and Dr Xianxin Hua including an exclusive option for IP arising from the research



CHM 2101 (CDH17 CAR T)

PROMISING PRECLINICAL SAFETY AND EFFICACY

CHM 2101 Preclinical Efficacy

CHM 2101 CAR T cells demonstrated complete eradication of tumor cells with no relapse



Assessment of tumor size in mice

CHM 2101 Preclinical Safety

CHM 2101 spared normal cells even when they expressed CDH17



OFF THE SHELF (ALLOGENEIC) NATURAL KILLER (NK) CELL PROGRAMS

CORE-NK PLATFORM

Clinically Validated, **O**ff the Shelf, **R**obust, **E**nhanced, **N**atural **K**iller Cell Platform

- An **off the shelf, natural killer cell platform**
- **A repeatable platform** that can be leveraged to develop unlimited new off the shelf, NK cell therapies
- **Complete Phase 1 clinical trial** in blood cancers and solid tumours
- **Multiple near-term development paths** in solid tumours and blood cancers



CORE-NK Platform Cells

Enhancing the Natural Cancer-Fighting Power of NK cells

Natural Killer (NK) Cell

Natural killer cells are found in our bodies normally and are able to recognize and kill cancer cells- but are not robust and active enough to overcome cancer as it grows

ACTIVATION AND EXPANSION OF HEALTHY DONOR NAKED NATURAL KILLER CELLS

nature

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells

CORE-NK Platform Cell



CORE-NK cells are made by activating and expanding natural killer cells to make them more active and robust in large quantities

CHM 0201 (CORE-NK Platform)

A Clinically Validated, Off the Shelf, Robust, Enhanced, Natural Killer Cell Platform

CORE-NK Platform Cell



CORE-NK cells are made by activating and expanding healthy donor natural killer cells with irradiated NKF feeder cells

CORE-NK Platform Differentiation	
Derived from a unique feeder cell line	✓
Development of master cell bank	✓
Demonstrated ability for robust ex vivo expansion	✓
Demonstrated metabolic activation	✓
Evidence of enhanced cytotoxic activity	✓
Successful manufacturing in large quantities	✓
Phase 1 Clinical Validation	✓

CORE-NK PLATFORM

PHASE 1 CLINICAL TRIAL COMPLETE

PATIENT ELIGIBILITY



Phase 1 Clinical Trial

Dr David Wald, Case Comprehensive Cancer Center

Study Initiation: May 2018

Primary Study Completion: June 2021

Data Availability: 2022

PHASE 1 DOSE ESCALATION



CHM 0201 (CORE-NK PLATFORM)

REPEATABLE TECHNOLOGY WITH MULTIPLE DEVELOPMENT PATHS



1. CORE-NK Combination Therapy

Rapid development in combination therapy

2. Next Generation CORE-NK Platform

Further enhancement with next generation technologies

3. CAR-NK Products

Fast-forward development of CAR NK products using our CLTX and CDH17 chimeric antigen receptors

4. Leverage the CORE-NK Platform

Identify collaborations or licensing opportunities to further expand the utilization of the CORE-NK platform

KEY RISKS

Key specific risks associated with Chimeric's business

Dependence upon Licence Agreements	Chimeric is reliant on the continuing operation of the Licence Agreements. A failure of a Licensor or Chimeric to comply with the terms of the Licence Agreement could have a material adverse effect on Chimeric's business, financial condition, operations or prospects.
Pipeline product in development and not approved for commercial sale	Chimeric's prospects of success is dependent on the success of clinical trials to obtain the regulatory approval for the CAR T technology, to be commercialised. Chimeric currently does not have a revenue stream from its product sales and does not expect to generate any such revenue in the short to medium term.
Clinical trial risk	Chimeric may be unable to secure the necessary approvals to conduct future clinical trials. There is also no assurance that products developed using the CAR T technology will be a success and not expose the company to product liability claims with unforeseen effects on clinical subjects. Unsuccessful clinical trial results could have a significant impact on the value of the Company's securities and the future commercial development of its technology.
Regulatory and reimbursement approvals	The research, development, manufacture, marketing and sale of products using the Company's technology are subject to varying degrees of regulation by a number of government authorities in the US, Australia and other countries. Products may also be submitted for reimbursement approval. The availability and timing of that approval may have an impact upon the uptake and profitability of products in some jurisdictions.
Commercialisation of products and potential market failure	Chimeric has not yet commercialised its technology and has no material revenue stream. The Company is also dependent on commercially attractive markets remaining available to it during the commercialisation phase and once developed to fund sufficient revenues for continued operation.
Dependence upon key personnel	Chimeric's key personnel is its primary asset and if any key personnel leave it may be difficult to replace them and may have a negative impact on the Company.

KEY RISKS

Key specific risks associated with Chimeric's business

Arrangements with third-party collaborators	The Company may collaborate with pharmaceutical and life science companies, academic institutions or other partners to complete the development and commercialisation of its products. If Chimeric is unable to collaborate with a third-party they would be required to develop and commercialise the CAR T technology at its own expense.
Risk of delay and continuity of operations	Chimeric may experience a delay in achieving critical milestones. Any material delays may impact adversely upon the Company, including the timing of any revenues under milestone or sales payments.
Competition	Companies in the US and other countries may already be pursuing the development of products that target the same markets that Chimeric is targeting and put them in direct competition with parties who have substantially greater resources than the Company.
Requirement to raise additional funds	The Company may be required to raise additional equity or debt capital in the future. As there is no assurance a raise will be successful when required, the Company may need to delay or scale down its operations.
Growth	The Company may be unable to manage its future growth successfully and continue to hire and retain the skilled personnel it requires.
Intellectual property	The Company's ability to leverage its innovation and expertise depends on its ability to continue to protect its intellectual property.

Chimeric's business is also subject to general risk factors.

Appendix: References For Potential Value Realization Pathways

ACQUISITIONS

1. https://www.gilead.com/news-and-press/press-room/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion
2. https://www.celgene.com/newsroom/cellular-immunotherapies/celgene-corporation-to-acquire-juno-therapeutics-inc/
3. https://www.astellas.com/en/news/15516
4. https://www.gilead.com/news-and-press/press-room/press-releases/2017/12/gilead-sciences-and-kite-to-acquire-cell-design-labs

PARTNERSHIPS

1. https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-worldwide-collaboration-janssen
2. https://www.gilead.com/news-and-press/press-room/press-releases/2021/6/kite-and-shoreline-biosciences-enter-into-strategic-partnership-to-develop-novel-allogeneic-cell-therapies
3. https://investors.vrtx.com/news-releases/news-release-details/vertex-pharmaceuticals-and-crispr-therapeutics-amend
4. https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-closing-vivo-gene-editing
5. https://www.artivabio.com/artiva-biotherapeutics-announces-exclusive-worldwide-collaboration-and-license-agreement-with-merck/
6. https://www.fiercebiotech.com/biotech/roche-s-genentech-to-pay-adaptimmune-150m-upfront-3b-or-more-biobucks-for-t-cell-therapies

INDEPENDENT DEVELOPMENT

1. https://www.globenewswire.com/news-release/2022/01/26/2373414/0/en/The-cell-and-gene-therapy-market-size-was-valued-at-USD-4-99-billion-in-2021-and-is-expected-to-reach-USD-36-92-billion-by-2027.html

CONTACT INFORMATION

Jennifer Chow
Chief Executive Officer
Chimeric Therapeutics Ltd
Cell: +1 908-723-8387
jchow@chimerictherapeutics.com

Paul A. Hopper
Executive Chairman
Chimeric Therapeutics Ltd
Cell: +61 406671515
paulhopper@lifescienceportfolio.com